Credit Suisse Starts Enhabit Home Health & Hospice (EHAB) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts EHAB Hot Sheet
Price: $13.80 --0%
Rating Summary:
1 Buy, 10 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 15 | New: 11
Rating Summary:
1 Buy, 10 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 15 | New: 11
Join SI Premium – FREE
Credit Suisse analyst A.J. Rice initiates coverage on Enhabit Home Health & Hospice (NYSE: EHAB) with a Neutral rating and a price target of $19.00.
For an analyst ratings summary and ratings history on Enhabit Home Health & Hospice click here. For more ratings news on Enhabit Home Health & Hospice click here.
Shares of Enhabit Home Health & Hospice closed at $15.85 yesterday.
You May Also Be Interested In
- Freedom Broker Starts MNTN Inc (MNTN) at Buy
- Stephens Starts Dropbox (DBX) at Equal Weight, 'Show Us Growth'
- Stifel Resumes Innate Pharma S.A. (IPH:FP) (IPHA) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
